IE41720B1 - Fungicidal and fungistatic compositions - Google Patents
Fungicidal and fungistatic compositionsInfo
- Publication number
- IE41720B1 IE41720B1 IE2058/75A IE205875A IE41720B1 IE 41720 B1 IE41720 B1 IE 41720B1 IE 2058/75 A IE2058/75 A IE 2058/75A IE 205875 A IE205875 A IE 205875A IE 41720 B1 IE41720 B1 IE 41720B1
- Authority
- IE
- Ireland
- Prior art keywords
- composition according
- fluorocytosine
- nystatin
- candicidin
- fungicidal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 230000000855 fungicidal effect Effects 0.000 title claims abstract description 15
- 230000001408 fungistatic effect Effects 0.000 title claims abstract description 11
- YKSVGLFNJPQDJE-YDMQLZBCSA-N (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4R,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-1,3,5,7,37-pentahydroxy-18-methyl-9,13,15-trioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid Chemical compound CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC2(O)CC(O)C(C(CC(O[C@@H]3O[C@H](C)[C@@H](O)[C@@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)O2)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1 YKSVGLFNJPQDJE-YDMQLZBCSA-N 0.000 claims abstract description 20
- 229960004348 candicidin Drugs 0.000 claims abstract description 19
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960004413 flucytosine Drugs 0.000 claims abstract description 17
- 229960000988 nystatin Drugs 0.000 claims abstract description 16
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 229930188428 trichomycin Natural products 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 150000004702 methyl esters Chemical class 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- -1 nystatin methyl ester Chemical class 0.000 claims description 3
- 239000012876 carrier material Substances 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 241000233866 Fungi Species 0.000 abstract description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 2
- 206010046914 Vaginal infection Diseases 0.000 abstract description 2
- 201000008100 Vaginitis Diseases 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 210000005000 reproductive tract Anatomy 0.000 abstract description 2
- 101000653791 Bos taurus Protein S100-A12 Proteins 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 210000004379 membrane Anatomy 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 229930182474 N-glycoside Natural products 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000003 vaginal tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001610364 Ovula Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241001085826 Sporotrichum Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1279774 | 1974-09-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE41720L IE41720L (en) | 1976-03-20 |
| IE41720B1 true IE41720B1 (en) | 1980-03-12 |
Family
ID=4386491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE2058/75A IE41720B1 (en) | 1974-09-20 | 1975-09-19 | Fungicidal and fungistatic compositions |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2317851T3 (da) * | 2008-08-01 | 2014-04-14 | Dow Agrosciences Llc | Anvendelse af 5-fluorcytosin som fungicid |
| CA2776562A1 (en) * | 2009-10-07 | 2011-04-14 | Dow Agrosciences Llc | Synergistic fungicidal composition containing 5-fluorocytosine for fungal control in cereals |
-
1975
- 1975-09-02 IL IL48039A patent/IL48039A0/xx unknown
- 1975-09-03 ZA ZA00755632A patent/ZA755632B/xx unknown
- 1975-09-04 AU AU84568/75A patent/AU476206B2/en not_active Expired
- 1975-09-12 DE DE19752540799 patent/DE2540799A1/de active Pending
- 1975-09-17 SE SE7510429A patent/SE7510429L/xx unknown
- 1975-09-18 FR FR7528601A patent/FR2285133A1/fr not_active Withdrawn
- 1975-09-18 LU LU73422A patent/LU73422A1/xx unknown
- 1975-09-18 NL NL7511001A patent/NL7511001A/xx not_active Application Discontinuation
- 1975-09-18 DD DD188429A patent/DD122023A5/xx unknown
- 1975-09-19 SU SU752172908A patent/SU607534A3/ru active
- 1975-09-19 IE IE2058/75A patent/IE41720B1/en unknown
- 1975-09-19 AT AT719775A patent/AT339471B/de not_active IP Right Cessation
- 1975-09-19 GB GB3852875A patent/GB1472046A/en not_active Expired
- 1975-09-19 BE BE160174A patent/BE833589A/xx unknown
- 1975-09-19 HU HU75HO00001836A patent/HU172247B/hu unknown
- 1975-09-20 CU CU7534348A patent/CU34348A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATA719775A (de) | 1977-02-15 |
| LU73422A1 (enrdf_load_html_response) | 1977-05-16 |
| HU172247B (hu) | 1978-07-28 |
| NL7511001A (nl) | 1976-03-23 |
| IE41720L (en) | 1976-03-20 |
| SE7510429L (sv) | 1976-03-22 |
| FR2285133A1 (fr) | 1976-04-16 |
| DD122023A5 (enrdf_load_html_response) | 1976-09-12 |
| AT339471B (de) | 1977-10-25 |
| DE2540799A1 (de) | 1976-04-01 |
| AU476206B2 (en) | 1976-09-16 |
| GB1472046A (en) | 1977-04-27 |
| BE833589A (fr) | 1976-03-19 |
| IL48039A0 (en) | 1975-11-25 |
| ZA755632B (en) | 1976-08-25 |
| SU607534A3 (ru) | 1978-05-15 |
| AU8456875A (en) | 1976-09-16 |
| CU34348A (es) | 1979-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4259314A (en) | Method and composition for the preparation of controlled long-acting pharmaceuticals | |
| CA2179682A1 (en) | Pharmaceutical, orally applicable composition | |
| DE69621776T2 (de) | Antitumorpräparate, die eine lipoteichonsäure aus streptococcus enthalten | |
| US9232793B2 (en) | Methods of inhibiting microbial growth using deoxyaldohexoses | |
| AU2002222296A1 (en) | Macrolide antibiotics | |
| IE41720B1 (en) | Fungicidal and fungistatic compositions | |
| WO2002005850A2 (en) | Enhancement of the action of anti-infective agents | |
| US4035568A (en) | Derivatives of polyene macrolide antibiotics | |
| US4000263A (en) | Erythromycin solution | |
| CA1134820A (en) | Triethyl citrate solutions of pge-type compounds | |
| SAWADA et al. | Mannan-mediated anticandidal activity of BMY-28864, a new water-soluble pradimicin derivative | |
| US4853372A (en) | Non-aqueous ivermectin formulation with improved antiparasitic activity | |
| US6696404B1 (en) | Antibacterial composition having xanthorrizol | |
| WO2016159537A1 (ko) | 파이토스핑고신 유도체 및 이를 함유하는 조성물 | |
| WO1996019489A1 (en) | Compounds | |
| JPS5834446B2 (ja) | 消炎剤 | |
| JP3720426B2 (ja) | アルコールデヒドロゲナーゼ阻害剤 | |
| US6235722B1 (en) | Pharmacological preparation | |
| EP0810198B1 (en) | Sesquiterpene compounds | |
| AU762097B2 (en) | Benzo(b)pyran derivatives useful as external agents for the skin | |
| EP3492071B1 (en) | Pharmaceutical composition comprising benzocaine with enhanced stability | |
| EP1011687A1 (en) | 13-deoxyanthracycline derivatives and processes for preparing them | |
| JP4011247B2 (ja) | 化粧料 | |
| US4039661A (en) | Antibiotic method of treating benign prostatic hypertrophy with sch-16656 | |
| US4173628A (en) | Method of treating benign prostatic hypertrophy with candimycin |